Nucala (mepolizumab) approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps – GSK
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for the treatment of chronic… read more.